37.86
0.53%
-0.20
After Hours:
36.35
-1.51
-3.99%
Collegium Pharmaceutical Inc stock is currently priced at $37.86, with a 24-hour trading volume of 361.82K.
It has seen a -0.53% decreased in the last 24 hours and a -2.40% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $37.85 pivot point. If it approaches the $38.49 resistance level, significant changes may occur.
Previous Close:
$38.06
Open:
$38.31
24h Volume:
361.82K
Market Cap:
$1.24B
Revenue:
$566.77M
Net Income/Loss:
$48.16M
P/E Ratio:
-102.32
EPS:
-0.37
Net Cash Flow:
$274.29M
1W Performance:
+0.93%
1M Performance:
-2.40%
6M Performance:
+55.16%
1Y Performance:
+60.90%
Collegium Pharmaceutical Inc Stock (COLL) Company Profile
Name
Collegium Pharmaceutical Inc
Sector
Phone
781-713-3699
Address
100 Technology Center Drive, Suite 300, Stoughton, MA
Collegium Pharmaceutical Inc Stock (COLL) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-04-24 | Downgrade | Jefferies | Buy → Hold |
Aug-25-23 | Reiterated | Needham | Buy |
May-02-23 | Resumed | Jefferies | Buy |
Aug-08-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
Feb-15-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Aug-06-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
Jul-14-20 | Initiated | BWS Financial | Sell |
May-27-20 | Initiated | Guggenheim | Neutral |
Feb-19-20 | Resumed | Jefferies | Buy |
Oct-30-19 | Reiterated | Needham | Buy |
May-03-19 | Resumed | H.C. Wainwright | Buy |
Apr-12-19 | Resumed | Janney | Buy |
Mar-20-19 | Initiated | SunTrust | Hold |
Jan-16-19 | Reiterated | Needham | Buy |
Mar-08-18 | Reiterated | H.C. Wainwright | Buy |
Feb-07-18 | Reiterated | Needham | Buy |
Dec-05-17 | Reiterated | Needham | Buy |
Sep-11-17 | Initiated | H.C. Wainwright | Buy |
May-11-17 | Reiterated | Needham | Buy |
Sep-13-16 | Initiated | Gabelli & Co | Buy |
Jun-01-15 | Initiated | Jefferies | Buy |
Jun-01-15 | Initiated | Needham | Buy |
Jun-01-15 | Initiated | Piper Jaffray | Overweight |
View All
Collegium Pharmaceutical Inc Stock (COLL) Latest News
Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks Investment Research
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Lag Estimates
Zacks Investment Research
Unlocking Q1 Potential of Collegium Pharmaceutical (COLL): Exploring Wall Street Estimates for Key Metrics
Zacks Investment Research
Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates
Zacks Investment Research
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Zacks Investment Research
Collegium (COLL) to Report Q1 Earnings: Here's What to Expect
Zacks Investment Research
Collegium Pharmaceutical Inc Stock (COLL) Financials Data
Collegium Pharmaceutical Inc (COLL) Revenue 2024
COLL reported a revenue (TTM) of $566.77 million for the quarter ending December 31, 2023, a +22.17% rise year-over-year.
Collegium Pharmaceutical Inc (COLL) Net Income 2024
COLL net income (TTM) was $48.16 million for the quarter ending December 31, 2023, a +292.60% increase year-over-year.
Collegium Pharmaceutical Inc (COLL) Cash Flow 2024
COLL recorded a free cash flow (TTM) of $274.29 million for the quarter ending December 31, 2023, a +123.71% increase year-over-year.
Collegium Pharmaceutical Inc (COLL) Earnings per Share 2024
COLL earnings per share (TTM) was $1.19 for the quarter ending December 31, 2023, a +260.81% growth year-over-year.
About Collegium Pharmaceutical Inc
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving. The company offers Xtampza, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. It is also developing Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older. In addition, the company offers Nucynta ER, an extended release formulation of tapentadol for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, such as neuropathic pain related to diabetic peripheral neuropathy in adults; and Nucynta IR, an immediate release formulation of tapentadol that is indicated for the management of moderate to severe acute pain in adults. Further, it is developing COL-195, an abuse-deterrent, extended-release hydrocodone for the treatment of chronic pain; COL-172, an abuse-deterrent, extended-release oxymorphone for the treatment of chronic pain; and COL-171, a proprietary preclinical DETERx extended-release, abuse-deterrent methylphenidate formulation for attention deficit hyperactivity disorder (ADHD), as well as COL-196, a morphine formulation. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Cap:
|
Volume (24h):